// App-Quantinova.ai

TPS2594 : A Phase 1 study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with advanced solid tumors.

Researchers

Presenter

  • Rebecca Sophie Kristeleit

Principal Investigators

  • Juanita Lopez

  • Sarah Slater

  • Manolo D'Arcangelo

  • Yvette Drew

  • Sola Adeleke

  • Jessica Brown

  • Donna Crawford

  • Nikolaos Diamantis

  • Paul Gougis

  • Alexandar Tzankov

  • Alison L. Hannah

  • Stephanie Anderson

  • Heidi A Lane

  • Anne Schmitt-Hoffmann

  • Martina Maurer

  • Felix Bachmann

  • Marc Frederick Engelhardt

  • Elizabeth R. Plummer

Medical Centers

  • Kings College London, London, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

  • Drug Development Unit, Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom

  • University Hospital Basel, Basel, Switzerland

  • Oncology Clinical Trial Consulting, Sebastopol, CA

  • Basilea Pharmaceutica International Ltd, Basel, Switzerland

Locations

  • United States

  • United Kingdom

  • Switzerland

Companies

  • Basilea Pharmaceutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Circulating endothelial cells

  • Circulating tumor cells

Drug/Treatment

  • BAL-101553

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02490800

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved